RIGLRigel Pharmaceuticals, Inc.

$541M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M+45.3% YoY

Gross Profit

$81M99.6% margin

Operating Income

$42M51.5% margin

Net Income

$40M48.8% margin

EPS (Diluted)

$2.20

QoQ Revenue Growth

+339.1%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$216M

Total Liabilities

$138M

Stockholders' Equity

$78M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$56M	+45.3%
Gross Profit	$81M	$56M	+45.1%
Operating Income	$42M	$21M	+98.6%
Net Income	$40M	$21M	+85.9%

Revenue Segments

Contract Revenues From Collaborations

$66M41%

License

$65M41%

Gross Product

$16M10%

Product

$12M8%

Government Contract

$3M2%

Research And Development Services And Others

$1M1%

Discounts And Allowances

-$4M-2%

RIGL Q1 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena